Vicplas International Ltd, listed on the SGX Mainboard, has reported a 9.4% increase in net profit for the first half of 2025, reaching S$245,000. This growth was accompanied by a 6.4% rise in revenue, totalling S$54.3m for the period ending 31 January 2025.
The company’s medical devices segment experienced a boost in performance due to increased orders from certain customers. However, this was offset by higher operating costs related to the expansion of its Changzhou plant and the start-up costs for a new facility in Mexico. Meanwhile, the pipes and pipe fittings segment benefited from robust activity in Singapore’s construction sector, although its performance was slightly affected by a cautious sales approach focusing on credit risk management.
Despite facing increased operating expenses, including a 16.6% rise in other operating costs and a 61.9% increase in finance costs, Vicplas managed to achieve a profit before tax of S$505,000, marking an 82.3% improvement from the previous year. The company’s adjusted EBITDA also saw a 9.5% increase, reaching S$4.4m.
Looking ahead, Vicplas International’s strategic focus on expanding its global footprint and managing operational costs will be crucial as it navigates the challenges and opportunities in its key markets.
“`
This news story was carefully selected and published by a human editor, though the content itself was AI-generated. If you spot an error, please report it here.
